NASDAQ: ANIKAnika Therapeutics Inc Stock
$14.72-0.23 (-1.54%)
Updated Jun 11, 2026
ANIK Price
$14.72
Fair Value Price
$21.42
Market Cap
$195.86M
52 Week Low
$7.87
52 Week High
$16.24
P/E
-18.63x
P/B
1.46x
P/S
1.69x
PEG
N/A
Dividend Yield
N/A
Revenue
$116.26M
Earnings
-$11.06M
Gross Margin
58.6%
Operating Margin
-8.81%
Profit Margin
-9.5%
Debt to Equity
0.34
Operating Cash Flow
$6M
Beta
0.83
Next Earnings
Jul 29, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ANIK Overview
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ANIK's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
ANIK
Ranked#17 of 94
Ranked#17 of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.68 | A | |
| $37.61 | A | |
| $26.35 | A |
Be the first to know about important ANIK news, forecast changes, insider trades & much more!
ANIK News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ANIK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANIK ($14.72) is undervalued by 31.28% relative to our estimate of its Fair Value price of $21.42 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ANIK ($14.72) is significantly undervalued by 31.28% relative to our estimate of its Fair Value price of $21.42 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ANIK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ANIK due diligence checks available for Premium users.
Valuation
ANIK fair value
Fair Value of ANIK stock based on Discounted Cash Flow (DCF)
Price
$14.72
Fair Value
$21.42
Undervalued by
31.28%
ANIK ($14.72) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ANIK ($14.72) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ANIK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ANIK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-18.63x
Industry
20.69x
Market
13.95x
ANIK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.46x
Industry
2.98x
ANIK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANIK's financial health
Profit margin
Revenue
$29.6M
Net Income
-$5.1M
Profit Margin
-17.1%
ANIK's Earnings (EBIT) of -$10.25M... subscribe to Premium to read more.
Interest Coverage Financials
ANIK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$179.4M
Liabilities
$45.5M
Debt to equity
0.34
ANIK's short-term assets ($93.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANIK's short-term assets ($93.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANIK's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ANIK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.8M
Investing
-$1.2M
Financing
-$10.3M
ANIK's operating cash flow ($6.47M)... subscribe to Premium to read more.
Debt Coverage Financials
ANIK vs Medical Device Stocks
Anika Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.